Literature DB >> 8608652

Effect of in vivo activation of natural killer (NK) cells by a tilorone analogue on the survival of mice injected intravenously with different experimental murine tumours.

I Algarra1, A González, M Pérez, J J Gaforio, F Garrido.   

Abstract

We studied the effect of a tilorone analogue (RMI 10,874DA) and anti-asialo GM(1) serum on the survival of BALB/c and C57B1/6 mice after i.v. injections of different syngeneic murine tumour cells. Tumour lines used were different clones from chemically (GR9 wild type, GR9.B9, B7.1.B4, B7.1.B5, B7.2.38), and ultraviolet light (GRUV3)-induced sarcomas; B16 melanoma and LSTRA and YC8 lymphomas. Pretreatment of mice with tilorone inhibited metastatic colonization and increased survival significantly in all cases. In some tumour systems, the effect was attenuated when high numbers of cells were injected. Abrogation of NK cells with anti-asialo GM(1) serum significantly decreased (in all tumours and at different cell doses) survival in comparison with untreated mice injected with tumours, regardless of cell dose used. These results clearly suggest that NK cell activation in vivo by the tilorone analogue we tested prolongs survival and inhibits metastasis formation in mice, even when pretreatment consists of a single dose of the analogue.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8608652      PMCID: PMC2200376          DOI: 10.1111/j.1365-2249.1996.tb08308.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  29 in total

1.  Proof without prejudice: use of the Kolmogorov-Smirnov test for the analysis of histograms from flow systems and other sources.

Authors:  I T Young
Journal:  J Histochem Cytochem       Date:  1977-07       Impact factor: 2.479

Review 2.  Natural killer cells as antitumor effector cells.

Authors:  R B Herberman; H T Holden
Journal:  J Natl Cancer Inst       Date:  1979-03       Impact factor: 13.506

3.  Antitumor activity of tilorone hydrochloride against some rodent tumors: preliminary report.

Authors:  R H Adamson
Journal:  J Natl Cancer Inst       Date:  1971-02       Impact factor: 13.506

4.  Effect of Tilorone hydrochloride and congeners on reticuloendothelial system, tumors, and the immune response.

Authors:  A E Munson; J A Munson; W Regelson; G L Wampler
Journal:  Cancer Res       Date:  1972-07       Impact factor: 12.701

5.  Enhanced NK cell activity in mice injected with interferon and interferon inducers.

Authors:  M Gidlund; A Orn; H Wigzell; A Senik; I Gresser
Journal:  Nature       Date:  1978-06-29       Impact factor: 49.962

Review 6.  Cancer metastasis. Organ colonization and the cell-surface properties of malignant cells.

Authors:  G L Nicolson
Journal:  Biochim Biophys Acta       Date:  1982-12-21

7.  Oligosaccharide ligands for NKR-P1 protein activate NK cells and cytotoxicity.

Authors:  K Bezouska; C T Yuen; J O'Brien; R A Childs; W Chai; A M Lawson; K Drbal; A Fiserová; M Pospísil; T Feizi
Journal:  Nature       Date:  1994-11-10       Impact factor: 49.962

8.  Role of NK cells in the control of metastatic spread and growth of tumor cells in mice.

Authors:  E Gorelik; R H Wiltrout; K Okumura; S Habu; R B Herberman
Journal:  Int J Cancer       Date:  1982-07-15       Impact factor: 7.396

Review 9.  The pathogenesis of cancer metastasis.

Authors:  G Poste; I J Fidler
Journal:  Nature       Date:  1980-01-10       Impact factor: 49.962

10.  Tilorone hydrochloride: an orally active antiviral agent.

Authors:  R E Krueger; G D Mayer
Journal:  Science       Date:  1970-09-18       Impact factor: 47.728

View more
  1 in total

1.  NK cells mediate increase of phagocytic activity but not of proinflammatory cytokine (interleukin-6 [IL-6], tumor necrosis factor alpha, and IL-12) production elicited in splenic macrophages by tilorone treatment of mice during acute systemic candidiasis.

Authors:  José Juan Gaforio; Elena Ortega; Ignacio Algarra; María José Serrano; Gerardo Alvarez de Cienfuegos
Journal:  Clin Diagn Lab Immunol       Date:  2002-11
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.